Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.
Gerecitano J, Portlock C, Moskowitz C, Hamlin P, Straus D, Zelenetz AD, Zhang Z, Dumitrescu O, Sarasohn D, Lin D, Pappanicholaou J, Cortelli BM, Neylon E, Hamelers R, Wright J, O'Connor OA. Gerecitano J, et al. Among authors: sarasohn d. Br J Haematol. 2009 Sep;146(6):652-5. doi: 10.1111/j.1365-2141.2009.07775.x. Epub 2009 Jul 16. Br J Haematol. 2009. PMID: 19624539 Free PMC article. Clinical Trial.
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.
O'Connor OA, Hamlin PA, Portlock C, Moskowitz CH, Noy A, Straus DJ, Macgregor-Cortelli B, Neylon E, Sarasohn D, Dumetrescu O, Mould DR, Fleischer M, Zelenetz AD, Sirotnak F, Horwitz S. O'Connor OA, et al. Among authors: sarasohn d. Br J Haematol. 2007 Nov;139(3):425-8. doi: 10.1111/j.1365-2141.2007.06658.x. Br J Haematol. 2007. PMID: 17910632 Free article. Clinical Trial.
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial.
O'Connor OA, Moskowitz C, Portlock C, Hamlin P, Straus D, Dumitrescu O, Sarasohn D, Gonen M, Butos J, Neylon E, Hamelers R, Mac-Gregor Cortelli B, Blumel S, Zelenetz AD, Gordon L, Wright JJ, Vose J, Cooper B, Winter J. O'Connor OA, et al. Among authors: sarasohn d. Br J Haematol. 2009 Apr;145(1):34-9. doi: 10.1111/j.1365-2141.2008.07466.x. Epub 2009 Feb 6. Br J Haematol. 2009. PMID: 19220284 Free article. Clinical Trial.
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
O'Connor OA, Horwitz S, Hamlin P, Portlock C, Moskowitz CH, Sarasohn D, Neylon E, Mastrella J, Hamelers R, Macgregor-Cortelli B, Patterson M, Seshan VE, Sirotnak F, Fleisher M, Mould DR, Saunders M, Zelenetz AD. O'Connor OA, et al. Among authors: sarasohn d. J Clin Oncol. 2009 Sep 10;27(26):4357-64. doi: 10.1200/JCO.2008.20.8470. Epub 2009 Aug 3. J Clin Oncol. 2009. PMID: 19652067 Free PMC article. Clinical Trial.
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.
O'Connor OA, Portlock C, Moskowitz C, Hamlin P, Straus D, Gerecitano J, Gonen M, Dumitrescu O, Sarasohn D, Butos J, Neylon E, Mac-Gregor Cortelli B, Blumel S, Evens AM, Zelenetz AD, Wright J, Cooper B, Winter J, Vose J. O'Connor OA, et al. Among authors: sarasohn d. Clin Cancer Res. 2010 Jan 15;16(2):719-26. doi: 10.1158/1078-0432.CCR-08-2647. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068103 Clinical Trial.
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
Gerecitano J, Portlock C, Hamlin P, Moskowitz CH, Noy A, Straus D, Schulman P, Dumitrescu O, Sarasohn D, Pappanicholaou J, Iasonos A, Zhang Z, Mo Q, Horanlli E, Rojas CN, Zelenetz AD, O'Connor OA. Gerecitano J, et al. Among authors: sarasohn d. Clin Cancer Res. 2011 Apr 15;17(8):2493-501. doi: 10.1158/1078-0432.CCR-10-1498. Epub 2011 Feb 23. Clin Cancer Res. 2011. PMID: 21346146 Free PMC article. Clinical Trial.
Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia.
Soff GA, Miao Y, Bendheim G, Batista J, Mones JV, Parameswaran R, Wilkins CR, Devlin SM, Abou-Alfa GK, Cercek A, Kemeny NE, Sarasohn DM, Mantha S. Soff GA, et al. Among authors: sarasohn dm. J Clin Oncol. 2019 Nov 1;37(31):2892-2898. doi: 10.1200/JCO.18.01931. Epub 2019 Sep 23. J Clin Oncol. 2019. PMID: 31545663 Free PMC article. Clinical Trial.
A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
Cadoo KA, Grisham RN, O'Cearbhaill RE, Boucicaut NN, Henson M, Iasonos A, Zhou Q, Sarasohn DM, Gallagher J, Kravetz S, Zamarin D, Makker V, Sabbatini PJ, Tew WP, Aghajanian C, Konner JA. Cadoo KA, et al. Among authors: sarasohn dm. Gynecol Oncol. 2020 Apr;157(1):214-221. doi: 10.1016/j.ygyno.2020.01.018. Epub 2020 Jan 17. Gynecol Oncol. 2020. PMID: 31959492 Free PMC article. Clinical Trial.
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study.
Rubinstein MM, Doria ER, Konner J, Lichtman S, Zhou Q, Iasonos A, Sarasohn D, Troso-Sandoval T, Friedman C, O'Cearbhaill R, Cadoo K, Kyi C, Cohen S, Soldan K, Billinson E, Caird I, Jang D, Eid K, Shah P, Guillen J, Aghajanian C, Zamarin D, Makker V. Rubinstein MM, et al. Among authors: sarasohn d. Gynecol Oncol. 2023 Feb;169:64-69. doi: 10.1016/j.ygyno.2022.11.028. Epub 2022 Dec 10. Gynecol Oncol. 2023. PMID: 36512912 Free PMC article. Clinical Trial.
Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller.
Chi DS, Barlin JN, Ramirez PT, Levenback CF, Mironov S, Sarasohn DM, Iyer RB, Dao F, Hricak H, Barakat RR. Chi DS, et al. Int J Gynecol Cancer. 2010 Apr;20(3):353-7. doi: 10.1111/IGC.0b013e3181d09fd6. Int J Gynecol Cancer. 2010. PMID: 20375796
28 results